Answer
Varilrix produces an attenuated, clinically inapparent chickenpox infection in susceptible individuals; antibodies are accepted as evidence of protection, although no protective antibody threshold has been established.
Sources for this answer
- VarilrixGlaxoSmithKline UK · emc · SmPC §5.1 Pharmacodynamic properties · Version 29Document updated
Sources checked